Clinical Trial Update: Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating niraparib in combination with dostarlimab for recurrent or progressive cervical cancer; the study is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Dostarlimab (dostarlimab)
• Niraparib (Niraparib)

Snippet

Sponsor: University of Oklahoma | Conditions: Recurrent Cervix Cancer, Progressive Cervix Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING